Soligenix Encourages Stockholders to Vote "FOR" Reverse Stock Split

Core Viewpoint - Soligenix, Inc. is urging its eligible stockholders to vote "FOR" a Reverse Stock Split to maintain its listing on The Nasdaq Capital Market, which is deemed crucial for attracting institutional support for its clinical programs [1][5]. Company Overview - Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products for rare diseases with unmet medical needs [5]. - The company is advancing its Specialized BioTherapeutics segment, particularly the HyBryte™ (SGX301) for cutaneous T-cell lymphoma, and is seeking regulatory approvals following the successful completion of its second Phase 3 study [5]. - Other development programs include SGX302 for psoriasis, dusquetide (SGX942) for inflammatory diseases, and SGX945 for Behçet's Disease [5]. Public Health Solutions - The Public Health Solutions segment includes the development of RiVax®, a ricin toxin vaccine, and vaccines targeting filoviruses and COVID-19 [6]. - This segment has received government funding from agencies such as NIAID, DTRA, and BARDA to support its vaccine programs [6]. Voting Information - Eligible stockholders can vote by contacting the company's proxy solicitor, and only those on record as of April 10, 2024, are eligible to participate [2]. - Stockholders who sold their shares after the record date are still encouraged to vote [2]. Proxy Materials - The company filed a definitive proxy statement and proxy card with the SEC on April 29, 2024, and stockholders are urged to read these documents for important information regarding the Annual Meeting [3][4].